Table 4.
Rate of a cure depending on the first-line treatment and surgery in the whole cohort; considering the whole court of patients, surgery (p < 0.0001), female sex (p < 0.0009), and size (p < 0.0182) strongly impacted the cure rate; surgery (p < 0.0005) and female sex (p < 0.0016) were confirmed significative for the subgroup with a follow-up >5 years.
| Whole Court | >5ys FU population | |||||||
|---|---|---|---|---|---|---|---|---|
| p-Value | Odds Ratio | 95% Lower | 95% Upper | p-Value | Odds Ratio | 95% Lower | 95% Upper | |
| Not cured: constant | 0.5143 | 0.751 | 0.318 | 1.776 | 0.5060 | 0.695 | 0.237 | 2.033 |
| Surgery: Yes | <0.0001 | 0.196 | 0.087 | 0.439 | 0.0005 | 0.158 | 0.056 | 0.445 |
| Age | 0.921 | 1.001 | 0.981 | 1.022 | 0.5640 | 1.007 | 0.982 | 1.033 |
| Sex: Female | 0.0009 | 0.323 | 0.166 | 0.627 | 0.0016 | 0.257 | 0.11 | 0.598 |
| Size: Micro-PRL-omas | 0.0182 | 0.469 | 0.250 | 0.879 | 0.0997 | 0.516 | 0.235 | 1.134 |
| I treatment: TSS | 0.6573 | 0.863 | 0.451 | 1.650 | 0.7586 | 1.131 | 0.516 | 2.475 |
| Knosp III and IV | 0.618 | 1.280 | 0.485 | 3.381 | 0.6406 | 0.758 | 0.237 | 2.427 |
Ys, years; FU, follow-up; TSS, trans-sphenoidal surgery; PRL, prolactin.